L-F Zhu1, L-D Song, Q Xu, J-F Zhan. 1. Department of Urology Surgery, The People's Hospital of Zhu Ji, Shao Xing, Zhejiang, China. zhss9118@aliyun.com.
Abstract
OBJECTIVE: Growing studies indicated that long non-coding RNAs (lncRNAs) acted as imperative players in neoplasms initiation and progression. This research was designed to study the potential involvements of lncRNA FEZF1-AS1 (FEZF1-AS1) in the pathogenesis of prostate cancer (PCa). PATIENTS AND METHODS: Real-time PCR was performed to detect the expressions of FEZF1-AS1 in PCa specimens and cell lines. Correlations between G- FEZF1-AS1 expressions and clinical characteristics and overall survivals were determined using statistical methods. The CCK-8 assays, colony formation assay, flow cytometry, transwell, and wound scratch assays were carried out to study cells viability, cells migration, and invasion. Western blot and RT-PCR were used for the determination of the influence of FEZF1-AS1 on Notch signaling pathway. RESULTS: We found that FEZF1-AS1 expressions were distinctly reduced in human PCa tissues and cell lines compared with their non-tumor counterparts, and its higher levels were strongly associated with lymph node metastasis (p=0.012) and Angiolymphatic invasion (p=0.022). Then, Kaplan-Meier assays showed that patients with higher expressions of FEZF1-AS1 were shown to predict unfavorable overall survival. Cox proportional hazards risks assays revealed that FEZF1-AS1 acted as an independent prognostic factor for PCa. Functional investigations suggested that knockdown of FEZF1-AS1 could suppress cells proliferation, trigger late apoptosis, and inhibit cells invasion and migration. Mechanistic assays demonstrated that FEZF1-AS1 exhibited its tumor-promotive roles by activating the Notch signaling pathway. CONCLUSIONS: We suggested that FEZF1-AS1 served as a tumor promoter in PCa and may develop a novel therapeutic target for PCa patients.
OBJECTIVE: Growing studies indicated that long non-coding RNAs (lncRNAs) acted as imperative players in neoplasms initiation and progression. This research was designed to study the potential involvements of lncRNA FEZF1-AS1 (FEZF1-AS1) in the pathogenesis of prostate cancer (PCa). PATIENTS AND METHODS: Real-time PCR was performed to detect the expressions of FEZF1-AS1 in PCa specimens and cell lines. Correlations between G- FEZF1-AS1 expressions and clinical characteristics and overall survivals were determined using statistical methods. The CCK-8 assays, colony formation assay, flow cytometry, transwell, and wound scratch assays were carried out to study cells viability, cells migration, and invasion. Western blot and RT-PCR were used for the determination of the influence of FEZF1-AS1 on Notch signaling pathway. RESULTS: We found that FEZF1-AS1 expressions were distinctly reduced in human PCa tissues and cell lines compared with their non-tumor counterparts, and its higher levels were strongly associated with lymph node metastasis (p=0.012) and Angiolymphatic invasion (p=0.022). Then, Kaplan-Meier assays showed that patients with higher expressions of FEZF1-AS1 were shown to predict unfavorable overall survival. Cox proportional hazards risks assays revealed that FEZF1-AS1 acted as an independent prognostic factor for PCa. Functional investigations suggested that knockdown of FEZF1-AS1 could suppress cells proliferation, trigger late apoptosis, and inhibit cells invasion and migration. Mechanistic assays demonstrated that FEZF1-AS1 exhibited its tumor-promotive roles by activating the Notch signaling pathway. CONCLUSIONS: We suggested that FEZF1-AS1 served as a tumor promoter in PCa and may develop a novel therapeutic target for PCa patients.